Added to YB: 2026-06-16
Pitch date: 2026-06-12
EWTX [bullish]
Edgewise Therapeutics, Inc.
-0.65%
current return
Author Info
BioEquity Watch is a free, independent publication offering in-depth analysis of biotech and pharmaceutical companies, focused on market-relevant research, IPOs, and drug development pipelines. Sign up for the newsletter.
Company Info
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders.
Market Cap
$3.7B
Pitch Price
$35.44
Price Target
54.00 (+53%)
Dividend
N/A
EV/EBITDA
-16.54
P/E
-20.96
EV/Sales
N/A
Sector
Pharmaceuticals
Category
special_situation
Edgewise Therapeutics: Is the lead asset sale brilliance or blunderous?
EWTX: $54 PT (+59% upside) on rNPV+cash SOTP. Sold muscular dystrophy pipeline to Servier for $1.55B upfront (~$25/sh net cash floor) + $1.1B milestones, becoming pure-play cardiac. Key catalyst: Q2'26 12-wk Ph2 CIRRUS-HCM data for EDG-7500 in HCM. Bear case: trial fails, $20-22/sh floor.
Read full article (6 min)